HC Wainwright set a $23.00 price objective on Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) in a research report sent to investors on Wednesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.
Separately, Zacks Investment Research upgraded Rexahn Pharmaceuticals from a hold rating to a strong-buy rating and set a $9.00 price target on the stock in a report on Friday, January 25th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of Buy and a consensus target price of $42.67.
Shares of NYSEAMERICAN:RNN opened at $6.30 on Wednesday. Rexahn Pharmaceuticals has a fifty-two week low of $4.75 and a fifty-two week high of $28.56.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.96) EPS for the quarter, beating the consensus estimate of ($1.56) by $0.60.
In related news, CEO Douglas J. Swirsky acquired 50,000 shares of the stock in a transaction dated Tuesday, January 29th. The shares were acquired at an average price of $0.63 per share, for a total transaction of $31,500.00. Following the completion of the purchase, the chief executive officer now owns 50,000 shares in the company, valued at approximately $31,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders bought 95,000 shares of company stock worth $60,050.
An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Virtu Financial LLC boosted its holdings in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 36.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,036 shares of the company’s stock after buying an additional 16,481 shares during the period. Virtu Financial LLC owned about 0.13% of Rexahn Pharmaceuticals worth $32,000 as of its most recent SEC filing.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.
Recommended Story: Cost of Capital
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.